Inhibikase Therapeutics Ownership 2024 | Who Owns Inhibikase Therapeutics Now?
Institutional Ownership
0.05%
Insider Ownership
12.02%
Retail Ownership
87.93%
Institutional Holders
1.00
Inhibikase Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HAMILTON LANE ADVISORS LLC | - | - | - | -13,802 | -100.00% | - | Sep 30, 2023 |
Inhibikase Therapeutics's largest institutional shareholder is HAMILTON LANE ADVISORS LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HAMILTON LANE ADVISORS LLC | - | - | - | -13,802 | -100.00% | - | Sep 30, 2023 |
The largest Inhibikase Therapeutics shareholder by % of total assets is HAMILTON LANE ADVISORS LLC. The company owns 0.00 shares of Inhibikase Therapeutics (IKT), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HAMILTON LANE ADVISORS LLC | - | - | - | -13,802 | -100.00% | - | Sep 30, 2023 |
As of Sep 30 2023, Inhibikase Therapeutics's largest institutional buyer is HAMILTON LANE ADVISORS LLC. The company purchased -13.80K stocks of IKT, valued at -.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HAMILTON LANE ADVISORS LLC | - | - | - | -13,802 | -100.00% | - | Sep 30, 2023 |
As of Sep 30 2023, Inhibikase Therapeutics's biggest institutional seller is HAMILTON LANE ADVISORS LLC. The company sold -13.80K shares of IKT, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HAMILTON LANE ADVISORS LLC | - | - | - | -13,802 | -100.00% | - | Sep 30, 2023 |
Inhibikase Therapeutics's largest sold out institutional shareholder by shares sold is HAMILTON LANE ADVISORS LLC, sold -13.80K shares, valued at -, as of undefined.
Inhibikase Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
360 Funds | 0.16% | 33,000 | - | - | Feb 29, 2024 |
360 Funds | 0.05% | 11,000 | 5,500 | 100.00% | Mar 31, 2024 |
VANGUARD VALLEY FORGE FUNDS | 0.02% | 11,895 | - | - | Mar 31, 2024 |
FIDELITY SELECT PORTFOLIOS | 0.01% | 433,300 | - | - | Feb 29, 2024 |
VANGUARD VALLEY FORGE FUNDS | 0.00% | 1,913 | - | - | Mar 31, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 510,292 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 81,120 | - | - | Feb 29, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 27,688 | -103 | -0.37% | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 16,724 | -73,577 | -81.48% | Mar 31, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 2,031 | - | - | Jan 31, 2024 |
iSHARES TRUST | 0.00% | 48,089 | - | - | Mar 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 3,408 | - | - | Mar 31, 2024 |
Inhibikase Therapeutics's largest mutual fund holder by % of total assets is "360 Funds", owning 33.00K shares, compromising 0.16% of its total assets.
Inhibikase Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Jun, 23 | 1 | -94.12% |
31 Mar, 23 | 17 | -10.53% |
31 Dec, 22 | 19 | -13.64% |
30 Sep, 22 | 22 | 10.00% |
30 Jun, 22 | 20 | -13.04% |
31 Mar, 22 | 23 | - |
31 Dec, 21 | 23 | 15.00% |
30 Sep, 21 | 20 | 53.85% |
30 Jun, 21 | 13 | 62.50% |
31 Mar, 21 | 8 | 60.00% |
31 Dec, 20 | 5 | - |
As of 30 Jun 23, 1 institutions are holding Inhibikase Therapeutics's shares, representing a decrease of -94.12% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Jun, 23 | 13,802 | -99.69% |
31 Mar, 23 | 4,421,111 | 206.88% |
31 Dec, 22 | 1,440,673 | -52.69% |
30 Sep, 22 | 3,045,355 | -9.10% |
30 Jun, 22 | 3,350,331 | -21.64% |
31 Mar, 22 | 4,275,402 | -8.23% |
31 Dec, 21 | 4,659,048 | 13.68% |
30 Sep, 21 | 4,098,248 | 8.00% |
30 Jun, 21 | 3,794,682 | 2233.62% |
31 Mar, 21 | 162,609 | 20.41% |
31 Dec, 20 | 135,050 | - |
Inhibikase Therapeutics (IKT) has 13.80K shares outstanding as of 30 Jun 23, down -99.69% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Jun, 23 | 0.05% | 0.02% |
31 Mar, 23 | 16.07% | 49.22% |
31 Dec, 22 | 5.71% | 3.92% |
30 Sep, 22 | 12.07% | 6.84% |
30 Jun, 22 | 13.28% | 4.62% |
31 Mar, 22 | 16.96% | 4.94% |
31 Dec, 21 | 18.53% | 6.97% |
30 Sep, 21 | 16.30% | 7.16% |
30 Jun, 21 | 15.09% | 3608.50% |
31 Mar, 21 | 0.65% | 224.19% |
31 Dec, 20 | 0.54% | - |
As of 30 Jun 23, Inhibikase Therapeutics is held by 0.05% institutional shareholders, representing a 0.02% growth compared to 31 Mar 23.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Jun, 23 | - | -100.00% |
31 Mar, 23 | 7 | -22.22% |
31 Dec, 22 | 9 | 80.00% |
30 Sep, 22 | 5 | -50.00% |
30 Jun, 22 | 10 | 25.00% |
31 Mar, 22 | 8 | -33.33% |
31 Dec, 21 | 12 | -14.29% |
30 Sep, 21 | 14 | 7.69% |
30 Jun, 21 | 13 | 160.00% |
31 Mar, 21 | 5 | - |
31 Dec, 20 | 5 | - |
- institutional shareholders have increased their position in IKT stock as of 30 Jun 23 compared to 7 in the previous quarter (a -100.00% decrease).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Jun, 23 | 1 | -50.00% |
31 Mar, 23 | 2 | -60.00% |
31 Dec, 22 | 5 | 25.00% |
30 Sep, 22 | 4 | - |
30 Jun, 22 | 4 | -33.33% |
31 Mar, 22 | 6 | 100.00% |
31 Dec, 21 | 3 | 200.00% |
30 Sep, 21 | 1 | - |
30 Jun, 21 | - | -100.00% |
31 Mar, 21 | 1 | - |
31 Dec, 20 | - | - |
1 institutional shareholders have reduced their position in IKT stock as of 30 Jun 23 compared to 2 in the previous quarter (a -50.00% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun, 23 | 1 | -94.12% | 13,802 | -99.69% | 0.05% | 0.02% | - | -100.00% | 1 | -50.00% |
31 Mar, 23 | 17 | -10.53% | 4,421,111 | 206.88% | 16.07% | 49.22% | 7 | -22.22% | 2 | -60.00% |
31 Dec, 22 | 19 | -13.64% | 1,440,673 | -52.69% | 5.71% | 3.92% | 9 | 80.00% | 5 | 25.00% |
30 Sep, 22 | 22 | 10.00% | 3,045,355 | -9.10% | 12.07% | 6.84% | 5 | -50.00% | 4 | - |
30 Jun, 22 | 20 | -13.04% | 3,350,331 | -21.64% | 13.28% | 4.62% | 10 | 25.00% | 4 | -33.33% |
31 Mar, 22 | 23 | - | 4,275,402 | -8.23% | 16.96% | 4.94% | 8 | -33.33% | 6 | 100.00% |
31 Dec, 21 | 23 | 15.00% | 4,659,048 | 13.68% | 18.53% | 6.97% | 12 | -14.29% | 3 | 200.00% |
30 Sep, 21 | 20 | 53.85% | 4,098,248 | 8.00% | 16.30% | 7.16% | 14 | 7.69% | 1 | - |
30 Jun, 21 | 13 | 62.50% | 3,794,682 | 2233.62% | 15.09% | 3608.50% | 13 | 160.00% | - | -100.00% |
31 Mar, 21 | 8 | 60.00% | 162,609 | 20.41% | 0.65% | 224.19% | 5 | - | 1 | - |
31 Dec, 20 | 5 | - | 135,050 | - | 0.54% | - | 5 | - | - | - |
Inhibikase Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Inhibikase Therapeutics's stock was made by Lees-Rolfe Garth on Apr 02 2024, selling 5,834 shares at $3.79 per share (valued at $22.11K). The last insider buy of IKT was made by Werner Milton H. on Aug 16 2022, buying 5,000 shares at $0.80 per share (worth $4.00K).
Inhibikase Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | 4 | - | - |
Q2 2024 | 2 | 1 | 200.00% |
Q2 2023 | 4 | - | - |
Q1 2023 | 2 | - | - |
Q3 2022 | 2 | - | - |
Q2 2022 | 10 | - | - |
Q1 2022 | 8 | 1 | 800.00% |
Q4 2021 | 5 | - | - |
Q3 2021 | 1 | 1 | 100.00% |
Q2 2021 | 5 | 2 | 250.00% |
Q4 2020 | 7 | 9 | 77.78% |
Q2 2011 | - | 2 | - |
4 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Inhibikase Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | - | - | - |
Q2 2024 | - | - | - |
Q2 2023 | - | - | - |
Q1 2023 | - | - | - |
Q3 2022 | 1 | - | - |
Q2 2022 | 3 | - | - |
Q1 2022 | - | - | - |
Q4 2021 | 5 | - | - |
Q3 2021 | - | - | - |
Q2 2021 | - | - | - |
Q4 2020 | - | - | - |
Q2 2011 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Inhibikase Therapeutics's stocks.
Inhibikase Therapeutics Peer Ownership
Ticker | Company |
---|---|
SIOX | Sio Gene Therapies Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
NTRB | Nutriband Inc. |
SCPH | scPharmaceuticals Inc. |
LGVN | Longeveron Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
MCRB | Seres Therapeutics, Inc. |
ANTX | AN2 Therapeutics, Inc. |
VRAX | Virax Biolabs Group Limited |
ONCY | Oncolytics Biotech Inc. |
RNXT | RenovoRx, Inc. |
DMAC | DiaMedica Therapeutics Inc. |
TPST | Tempest Therapeutics, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
MIST | Milestone Pharmaceuticals Inc. |
LIFE | aTyr Pharma, Inc. |
IKT Ownership FAQ
Who Owns Inhibikase Therapeutics?
Inhibikase Therapeutics is owned by institutional shareholders (0.05%), insiders (12.02%), and public (87.93%). The largest institutional shareholder of Inhibikase Therapeutics is HAMILTON LANE ADVISORS LLC (0% of total shares) and the top mutual fund owner is 360 Funds (0.16% of total shares).
Who are the major institutional shareholders of Inhibikase Therapeutics?
Inhibikase Therapeutics's major institutional shareholders are HAMILTON LANE ADVISORS LLC. The top five shareholders own together 0% of the company's share outstanding.
How many Inhibikase Therapeutics shareholders are there?
As of Jun 2023, there are 1 institutional shareholders of Inhibikase Therapeutics.
What percentage of Inhibikase Therapeutics is owned by HAMILTON LANE ADVISORS LLC?
HAMILTON LANE ADVISORS LLC owns 0 shares of Inhibikase Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Sep 2023).